Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Genscript Biotech ( (HK:1548) ) has provided an update.
Genscript Biotech Corporation has announced its 2025 Annual General Meeting, scheduled for May 29, 2025, in Nanjing, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements, re-election of board members, and re-appointment of auditors. Additionally, the company seeks approval to allow its directors to issue new shares, a move that could potentially impact its capital structure and shareholder value.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, primarily operating in the biotechnology industry. The company focuses on providing a range of biotech products and services, including gene synthesis, peptide synthesis, protein production, and antibody development, catering to the needs of the life sciences research and pharmaceutical sectors.
YTD Price Performance: 23.23%
Average Trading Volume: 3,849
Technical Sentiment Signal: Buy
Current Market Cap: $3.37B
See more data about 1548 stock on TipRanks’ Stock Analysis page.